Public Sector Pension Investment Board Buys 24,913 Shares of BioLife Solutions, Inc. $BLFS

Public Sector Pension Investment Board increased its stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 19.7% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 151,378 shares of the medical equipment provider’s stock after purchasing an additional 24,913 shares during the period. Public Sector Pension Investment Board owned 0.32% of BioLife Solutions worth $3,862,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Hantz Financial Services Inc. increased its position in shares of BioLife Solutions by 54.1% during the third quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider’s stock valued at $48,000 after buying an additional 659 shares during the period. Ameritas Investment Partners Inc. grew its stake in BioLife Solutions by 12.8% during the second quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock valued at $83,000 after acquiring an additional 441 shares in the last quarter. AlphaQuest LLC purchased a new position in BioLife Solutions during the second quarter valued at approximately $149,000. Strs Ohio bought a new stake in BioLife Solutions during the 1st quarter worth approximately $153,000. Finally, Tower Research Capital LLC TRC lifted its stake in BioLife Solutions by 547.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,133 shares of the medical equipment provider’s stock worth $154,000 after purchasing an additional 6,032 shares in the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Insider Activity

In other news, Director Amy Duross sold 2,000 shares of the stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $27.00, for a total transaction of $54,000.00. Following the transaction, the director directly owned 22,687 shares in the company, valued at approximately $612,549. This represents a 8.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Troy Wichterman sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $25.72, for a total value of $771,600.00. Following the completion of the sale, the chief financial officer owned 152,769 shares of the company’s stock, valued at $3,929,218.68. The trade was a 16.41% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 42,005 shares of company stock worth $1,080,100 over the last quarter. Corporate insiders own 2.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on BLFS. UBS Group restated a “buy” rating on shares of BioLife Solutions in a research report on Monday, December 29th. Wall Street Zen lowered BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Sunday, November 30th. HC Wainwright restated a “buy” rating and set a $32.00 target price on shares of BioLife Solutions in a research report on Monday, December 29th. Weiss Ratings restated a “sell (d-)” rating on shares of BioLife Solutions in a research note on Wednesday, January 21st. Finally, Northland Securities set a $34.00 price target on BioLife Solutions in a research report on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

BioLife Solutions Stock Performance

Shares of NASDAQ:BLFS opened at $23.09 on Friday. The firm has a market capitalization of $1.11 billion, a PE ratio of -329.81 and a beta of 1.92. BioLife Solutions, Inc. has a 52-week low of $19.10 and a 52-week high of $29.62. The firm has a fifty day moving average of $24.03 and a 200 day moving average of $25.16.

BioLife Solutions Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.